CYP1B1 nucleic acids and methods of use

Details CYP1B1 nucleic acids and methods of use CYP1B1 nucleic acids and methods of use

2007-07-10

2007-07-10

Blanchard, David J. (Department: 1643)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S093200, C424S093210, C424S094100, C435S069100, C435S069300, C435S320100, C435S440000, C536S023100, C536S023200

Reexamination Certificate

active

09999686

ABSTRACT:
The present invention provides nucleic acids containing transcriptional units that encode CYP1B1 polypeptides or portions thereof, wherein the transcriptional units lack sequences found in the untranslated region (UTR) of naturally occurring forms of the CYP1B1 transcript. The nucleic acids of the invention lack translational repressor elements and thus provide for a system of enhanced translation of the CYP1B1 polypeptide or portions thereof. Also disclosed are methods of administering nucleic acids to a mammal and use in the treatment of proliferative disorders or cancer.

REFERENCES:
patent: 5539084 (1996-07-01), Geysen
patent: 5679647 (1997-10-01), Carson et al.
patent: 5783567 (1998-07-01), Hedley et al.
patent: 5807978 (1998-09-01), Kokolus et al.
patent: 5840839 (1998-11-01), Wang et al.
patent: 6130077 (2000-10-01), Yue et al.
patent: 6242203 (2001-06-01), Melvin et al.
patent: WO 95/05849 (1995-03-01), None
patent: WO 97/12246 (1997-04-01), None
patent: WO 98/36098 (1998-08-01), None
patent: WO 00/56773 (2000-09-01), None
patent: WO 01/35810 (2001-05-01), None
patent: WO 01/58444 (2001-08-01), None
patent: WO 01/79468 (2001-10-01), None
Tuting et al. Journal of Molecular Medicine, 75:478-491, 1997.
Reiger et al. Glossary of Genetics and Cytogenetics, Classical and Molecular, 4th Ed., Springer-Verlay, Berlin, 1976.
Riott et al. Immunology, Fourth Edition, 1996, Mosby, p. 7.9-7.11.
Sonenberg et al. Cell, 27:563-572, 1981.
Lawrence et al. Journal of Clinical Investigation, 102(6):1258-1264, 1998.
Crystal R. G. Science, 270(5235):404-409, Oct. 20, 1995.
Walther et al. Drugs. 60(2):249-271, Aug. 2000.
Vile et al. Gene Therapy, (7):2-8, 2000.
Rochlitz C. F. Swiss Medicine Weekly, 131:4-9, 2001.
Verma et al. Nature, vol. 389, pp. 239-242, 1997.
Lunsford et al. Journal of Drug Targeting, 8(1):39-50, Apr. 2000.
Luby et al. Clinical Immunology, 112(1):45-53, 2004.
Gregoriadis G. Current Opinion in Molecular Therapy, 1(1):39-42, Feb. 1999.
Murray et al. Cancer Research, 57:3026-3031, Jul. 15, 1997.
Albin et al., “Main Drug-metabolizing Enzyme Systems in Human Breast Tumors and Peritumoral Tissues,” Cancer Research, 53:3541-3546, Aug. 1, 1993.
Aziz & Munro, “Iron regulates ferritin MRNA translation through a segment of its 5′ untranslated region,” Proc. Natl. Acad. Sci. USA, 84:8478-8482, Dec. 1987.
Benton & Kennedy, “DNA vaccine strategies for the treatment of cancer,” Curr. Top. Microbiol. Immunol., 226:1-20, 1998.
Buchmann et al., “Development of Cytochrome P-450-altered Preneoplastic and Neoplastic Lesions during Nitrosamine-induced Hepatocarcinogenesis in the Rat,” Cancer Research, 47:2911-2918, Jun. 1, 1987.
Czerwinski et al., “Quantification of CYP2B7, CYP4B1, and CYPOR Messenger RNAs in Normal Human Lung and Lung Tumors,” Cancer Research, 54:1085-1091, Feb. 15, 1994.
Dela Cruz et al., “Xenogeneic and allogeneic anti-MHC immune responses induced by plasmid DNA immunization,” Vaccine, 17:2479-2492, 1999.
Duenas et al., “In vitro immunization of naive human B cells yields high affinity immunoglobulin B antibodies as illustrated by phase display,” Immunol., 89:1-7, 1996.
Gagliardi et al., “Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T-lymphocytes,” Internat. Immunol., 7(11):1741-1752, 1995.
Hanke et al., “DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: Immunogenocity in mice vaccine,” 16:436-435, 1998.
Jansson et al., “Enhanced expression of CYP1B1 inEscherichia coli,” Toxicology, 144:211-219, 2000.
Knuth et al., “Cancer immunotheraphy in clinical oncology,” Cancer Chemother Pharmacol., 46(Suppl)S46-S51, 2000.
McFadyen et al., “Immunohistochemical Localization of Cytochrome P450 CYP1B1 in Breast Cancer with Monoclonal Antibodies Specific for CYP1B1,” J. Histochemistry & Cytochemistry, 47(11):1457-1464, 1999.
McKay et al., “Expression of cytochrome P450 CYP1B1 in breast cancer,” FEBS Letters, 374:270-272, 1995.
Minnerath et al., “The BALB/c mouse B-cell response to pigeon cytochromecinitiates as a heteroclitic response specific for the self antigen mouse cytochromec, ” Immunology, 92:12379-12383, Dec. 1995.
Murray et al., “Cytochrome P450 expression is a common molecular event in soft tissue sarcomas,” J. Pathol., 171:49-52, 1993.
Murray et al., “Tumor-specific expression of cytochrome P450 CYP1B1,” Cancer Research, 57:3026-31, Jul. 15, 1997.
Ribas et al., “Generation of T-Cell Immunity to a Murine Melanoma Using MART-1-Engineered Dendritic Cells,” Journal of Immunotherapy, 23(1):59-66, 2000.
Sarfarazi, “Recent advances in molecular genetics of glaucomas,” Human Molecular Genetics, 6(10):1667-1677, 1997.
Shimada et al., Recombinant Human Cytochrome P450 1B1 Expression inEscherichia coli, Archives of Biochemistry and Biophysics, 357(1):111-120, Sep. 1, 1998.
Spooner et al., “DNA vaccination for cancer treatment,” Gene Therapy, 2:173-180, 1995.
Steitz et al., “Genetic Immunization of Mice with Human Tyrosinase-related Protein 2: Implications for the Immunotherapy of Melanoma,” Int. J. Cancer, 86:89-94, 2000.
Stevenson, “DNA vaccines against cancer: from genes to therapy,” Ann. Oncol., 10:1413-1418, 1999.
Stoilov et al., “Identification of three different runcating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (buphthalmos) in families linked to the GLC3A locus on chromosome 2p21,” Human Molecular Genetics, 6(4):641-647, 1997.
Sutter et al., “Complete cDNA sequence of a human-dioxin inducible mRNA identifies a new gene subfamily of cytochrome p450 that maps to chromosome 2,” J. Biol. Chem., 269(18):13092-13099, 1994.
Tang et al., “Isolation and Characterization of the Human CytochromeP450 CYP1B1Gene,” J. Biological Chemistry, 271(45):28324-28330, Nov. 8, 1996.
Taylor et al., “Cytochrome P450 IBI expression in human malignant tumors,” Biochem. Society Transactions, 24:328S, 1996.
Weber et al., “Tumor immunity and autoimmunity induced by immunization with homologous DNA,” J. Clin. Invest., 102(6):1258-1264, Sep. 1998.
Xiang et al., “An autologous oral DNA vaccine protects against murine melanoma,” Proc. Natl. Acad. Sci., 97(10):5492-5497, May 9, 2000.
Zhang et al., “Characterization of the MouseCyp1B1Gene,” J. Biological Chemistry, 273(9):5174-5183, Feb. 27, 1998.
Zhou et al., “Protective immunization against melanoma by gp100 DNA-HVJ-liposome vaccine,” Gene Therapy, 6:1768-1773, 1999.
Zuber et al., “Induction of Immune Responses and Break of Tolerance by DNA against the HIV-1 Coreceptor CCR5 but No Protection from SIVsm Challenge,” Virology, 278:400-411, 2000.
GenBank™ Accession No. U03688, Jul. 6, 1994.
Shehin et al., “Transcriptional Regulation of the HumanCYP1B1 Gene; Evidence for Involvement of an Aryl Hydrocarbon Receptor Response Element in Constitutive Expression”,The Journal of Biological Chemistry, 275 (10): 6770-6776 (2000).

Affiliated with

Also associated with

Rating

CYP1B1 nucleic acids and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with CYP1B1 nucleic acids and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CYP1B1 nucleic acids and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3782202